BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Amilpar Acquisition of Lincx


5/26/2011 8:46:04 AM

AMIL PARTICIPACOES S.A. (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ; Reuters: AMIL3 SA), the largest healthcare operator in Brazil, informs that signed today through its subsidiary Amil Assistencia Medica Internacional S.A. ("Amil"), a Purchase Agreement with the controlling shareholders of Lincx Sistemas de Saude Ltda. ("Lincx") for the acquisition and transference of up to 100% of their interest in that company.

The amount to be paid for the acquisition, subject to confirmation after the auditing process, is R$ 170 million and should be made in 4 installments. Lincx has approximately R$ 20 million in cash, which will be part of the assets acquired reducing the Equity Value to roughly R$ 150 million and has no financial debt.

Lincx annualized revenues in 2011 are close to R$ 220 million with an EBITDA margin of approximately 8% (without synergies). The company has a portfolio with 36,000 members, 30,000 of which in health plans (being approximately 76% of corporate clients) and 6,000 in dental plans, operates mainly in the state of Sao Paulo, with branches in Londrina (state of Parana) and Rio de Janeiro, in the Premium segment focused in high income clients for 18 years.

Before this acquisition, AMILPAR already served the high income segment through its own brand AMIL ONE, launched in 2010, and now our presence in this market will increase significantly. It is important to highlight that all contracts previously undertaken by Lincx will be respected and that, from now on, all Lincx's stakeholders, specially doctors and beneficiaries, will count with even more solidity for being with the largest private healthcare company in Brazil.

The effectiveness of this acquisition is subject to the approval of the Brazilian Healthcare Agency - ANS ("Suspensive Condition"). This deal will also be submitted to the analysis of the Brazilian System of Competition Defense (CADE).

To access the .pdf full version of the document, visit our website at www.amilpar.com.br/ir

IR CONTACT
Erwin Kleuser
Investor Relations Officer
Phone: +55 (21) 3805-1155
invest@amil.com.br
www.amilpar.com.br/ir

ABOUT AMILPAR

AMIL PARTICIPACOES S.A. is the largest healthcare operator in Brazil, according to the ANS, currently assisting over 5.5 million members in the states of Sao Paulo, Rio de Janeiro, Parana, Minas Gerais, Pernambuco, Bahia, Rio Grande do Norte and in Distrito Federal.

SOURCE AMILPAR



Read at BioSpace.com

Amilpar
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES